TLR2 and neoplasm: Also, since supplementation with TLR2 ligands during DSS-induced colitis is shown to promote transepithelial resistance and thereby protect from colitis [8], treatment with TLR2 ligands during the full course of AOM-DSS could result in a reduction of tumor development.